drugset
drugset / Trial / NCT01806896

Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease

NCT01806896 ↗

Phase 2 Completed 37 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.

Timeline

Start
2013-09
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MARDEPODECT Small molecule 5 mg Oral
Subject MARDEPODECT Small molecule 20 mg Oral

Indications

Huntington disease